+ Follow SPIRIVA Tag
SPIRIVA
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 613385
[Title] => Spiriva as good as Serevent in asthma study
[Summary] => Researchers say they've found a possible new treatment for adults with hard-to-control asthma. Their discovery, however, came at a price.
[DatePublished] => 2010-09-20 12:43:51
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[1] => Array
(
[ArticleID] => 168699
[Title] => Breakthrough drug for COPD out
[Summary] => Two pharmaceutical companies, Boehringer Ingelheim and Pfizer, recently introduced Tiotropium, a novel drug that will provide remedy to patients suffering from Chronic Obstructive Pulmonary Disorder (COPD).
Tiotropium is the first once-daily inhaled therapy for the maintenance and treatment of COPD.
While it is less known than asthma, COPD is far more prevalent. World Health Organization (WHO) studies state that there are 600 million people suffering from COPD, although most remain undiagnosed.
[DatePublished] => 2002-07-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 164478
[Title] => COPD therapy introduced in RP
[Summary] => The novel once-daily inhaled treatment tiotropium (Spiriva) for treating chronic obstructive pulmonary disease (COPD) has been introduced in the Netherlands and the Philippines. Launches in Germany, Sweden, Denmark and Finland will follow this month.
Spiriva (tiotropium) is approved as a bronchodilator for the maintenance treatment of COPD. Discovered and developed by Boehringer Ingelheim, Spiriva is the first once-daily inhaled therapy for COPD.
[DatePublished] => 2002-06-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 136000
[Title] => Tiotropium effective for COPD — study
[Summary] => BERLIN, Germany — Tiotropium was shown effective in treating patients with chronic obstructive pulmonary disease (COPD), according to data from a long-term clinical trial presented here at the annual meeting of the European Respiratory Society.
Tiotropium, a once-daily inhaled anticholinergic, was found superior to the long-acting beta agonist salmeterol in several key aspects.
[DatePublished] => 2001-10-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 83359
[Title] => Partnership on COPD treatment bared
[Summary] => Boehringer Ingelheim and Pfizer Inc. have entered into a long-term worldwide agreement to jointly market Spiriva (tiotropium), a novel once-a-day inhaled treatment for Chronic Obstructive Pulmonary Disease (COPD), which includes chronic bronchitis and emphysema.
Boehringer Ingelheim has filed for marketing approval with regulatory authorities in Europe, where Spiriva could be available as early as mid-2002.
A new drug application for Spiriva is anticipated to be filed with the US Food and Drug Administration later this year.
[DatePublished] => 2001-04-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
September 20, 2010 - 12:43pm
October 8, 2001 - 12:00am
